Table 2.

mOS and mPFS of patients with BMs from lung adenocarcinoma after icotinib treatment

	Total (N=28)	Treatment-naïve patients (n=11)	Retreated patients (n=17)	Patients with EGFR gene mutations (n=12)	Patients with unknown EGFR gene status (n=16)
mOS (months)	21.1	15.2	21.2	21.2	20.4
Range	2.9–33.6	2.9–31.5	6.2–33.6	6.2–31.5	2.9–33.6
95% CI	16.6–25.6	6.0–24.4	17.2–25.2	10.2–32.2	15.9–24.9
mPFS (months)	10.9	14.4	10.5	12.4	10.0
Range	1.1–31.5	1.1–31.5	2.1–23.9	4.8–31.5	1.1–23.9
95% CI	9.7–12.0	6.8–21.9	9.2–11.8	8.1–16.7	6.4–13.6

Abbreviations: mOS, median overall survival; mPFS, median progression-free survival; BMs, brain metastases; EGFR, epidermal growth factor receptor; CI, confidence interval.